Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 3,713 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Muscle Disorders Clear all

Conditions: SCD
Interventions: Non-Invasive Infrared Spectroscopy; Diagnostic Test
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dupuytren's Contracture
Interventions: collagenase clostridium histolyticum, Placebo; Biological
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 12 more

Conditions: Cerebrovascular Accident
Interventions: Control, Experimental; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Epilepsy
Interventions: electrical stimulation of vagus nerve; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Uterine Fibroids
Interventions: Vilaprisan (BAY1002670), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 52
States / cities: Birmingham, Alabama • Arcadia, California • Cerritos, California + 43 more

Conditions: Fibrodysplasia Ossificans Progressiva
Interventions: Andecaliximab, Placebo; Drug
Lead sponsor: Ashibio Inc; Industry
Eligibility: 2 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania

Conditions: Fibromyalgia, FMS
Interventions: Light therapy A (Bright) via the Re-Timer®, Light therapy B (Dim) via the Re-Timer®; Device
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic, Small Cell Lung Cancer
Interventions: BBI-355, Erlotinib, Futibatinib, BBI-825; Drug
Lead sponsor: Boundless Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 16
States / cities: Los Angeles, California • Santa Monica, California • Denver, Colorado + 12 more

Conditions: Amyotrophic Lateral Sclerosis, Hereditary Spastic Paraplegia, Primary Lateral Sclerosis, Progressive Muscular Atrophy, Frontotemporal Dementia
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 7 Years and older
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2031
U.S. locations: 3
States / cities: Miami, Florida • Kansas City, Kansas • Philadelphia, Pennsylvania

Conditions: Spinal Cord Injury Cervical, Stroke
Interventions: Motion and Emg Control; Device
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 16 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: ICU Acquired Weakness
Interventions: Clinical Electrical Stimulator; Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne, Muscular Dystrophy (DMD), DMD, Muscular Dystrophies, Muscular Dystrophy in Children, Muscular Dystrophy, Duchenne Type, Muscular Dystrophy, Duchenne and Becker Types, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy), Genetic Disease, Inborn, Genetic Disease, X-Linked, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neuromuscular Diseases (NMD)
Interventions: Zeleciment Rostudirsen (DYNE-251), Placebo; Drug
Lead sponsor: Dyne Therapeutics; Industry
Eligibility: 4 Years to 18 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Hillsborough, North Carolina

Conditions: Gulf War Illness, Persian Gulf Syndrome
Interventions: Submaximal bicycle exercise stress tests performed 24 hr apart; Diagnostic Test
Lead sponsor: Georgetown University; Other
Eligibility: 38 Years to 86 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Duchenne Muscular Dystrophy
Interventions: delandistrogene moxeparvovec; Genetic
Lead sponsor: Sarepta Therapeutics, Inc.; Industry
Eligibility: 3 Months to 7 Years · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sarcoma, Soft Tissue, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Myxofibrosarcoma, Angiosarcoma, Fibrosarcoma, Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma
Interventions: Dexrazoxane, Doxorubicin; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Sarcopenia
Interventions: Testosterone injection, Testosterone gel, Medrol; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 60 Years to 85 Years · Male only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Breast Cancer, Breast Cancer Female, Muscle Weakness
Interventions: Creatine; Dietary Supplement
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Pain, Anxiety, Musculoskeletal Pain, Sensitisation
Interventions: No intervention; Other
Lead sponsor: Philadelphia College of Osteopathic Medicine; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Suwanee, Georgia

Conditions: Myotonic Dystrophy
Interventions: SAR446268; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 10 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 5
States / cities: Gainesville, Florida • Tampa, Florida • New York, New York + 2 more

Conditions: Obstructive Sleep Apnea, Hypertension
Interventions: Inspiratory Muscle Strength Training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 50 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Arthralgia, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration, assessment of therapy complications; Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Myotonic Dystrophy Type 1
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Arterial Disease, Peripheral Artery Disease
Interventions: MitoQ; Dietary Supplement
Lead sponsor: University of Nebraska; Other
Eligibility: 50 Years to 85 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Bladder Cancer
Interventions: Abraxane; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Exploring Near Infrared Spectroscopy (NIRS) Technologies for Assessment of Muscle Physiology, Tissue Oxygenation, and Blood Flow in Patients With Sickle Cell Disease (SCD)

AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Dupuytren's Contracture

Mechanisms of Upper-Extremity Motor Recovery in Post-stroke Hemiparesis

Systematic Evaluation of VNS Parameters

Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Light Treatment to Improve Symptom Management of Fibromyalgia Syndrome

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Phenotype, Genotype and Biomarkers 2

BoMI for Muscle Control

Diagnosing Intensive Care Unit (ICU) Acquired Weakness

Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

Exercise in Gulf War Illness (GWI)

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

THRIVE Well Cancer FDTN/Exercise_Creatine Supplementation

The Effect of State and Trait Anxiety on Pain-pressure Threshold

A Study to Investigate the Safety, Tolerability, and Efficacy of SAR446268, an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Aged 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1

Breathing Training for Improving Cardiovascular Health in Older Adults With Sleep Apnea

Role of Biomarkers in Muscle Pain and Joint Pain in Patients With Solid Tumors Receiving Paclitaxel

Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer